ArriVent Biopharma, Inc. (AVBP)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$30.95-0.26%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · AVBP
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
AVBP — earnings miss
Dated 2026-05-11
and in the press release furnished as Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended, or incorporated by reference in any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation langua…
Why it matters: Topline data for firmonertinib in NSCLC will show if it can be a first-line treatment.
Supportive ifThe FURVENT Phase 3 study shows good results.
Worry ifThe FURVENT Phase 3 study shows bad or unclear results.
Why it matters: Good data could help the ADC pipeline and support the company's plan.
Supportive ifEarly Phase 1 data for ARR-217 shows good safety and effectiveness.
Worry ifInitial Phase 1 data for ARR-217 shows safety concerns or lack of efficacy.
Why it matters: Dosing the first patient will mark a key step in advancing this promising ADC.
Supportive ifFirst patient with ARR-002 is dosed in the Phase 1 trial as planned.
Worry ifDosing of the first patient with ARR-002 is delayed or canceled.
Why it matters: Enrollment progress will show how well the study is going and when results may come.
Watch forEnrollment in the ALPACCA Phase 3 study is speeding up and meeting goals.
Also watch forEnrollment in the ALPACCA Phase 3 study stagnates or slows down.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$130 on $10,000 · ±1.3% | How much price usually moves either way. |
| Bad day | $509 loss on $10,000 · 5.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,422 loss on $10,000 · 24.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.